Pfizer Hikes 2025 Profit Outlook On Cost Cuts, Strong Quarterly Results

Pfizer raised its full-year adjusted profit guidance on the back of cost reductions and strong business performance this year, Annika Kim Constantino reported for CNBC.

Pfizer now expects full-year adjusted profit to be between $2.90 and $3.10 per share (Photo: International Society for Pharmaceutical Engineering (ISPE)) 

The company also reported second-quarter results that topped Wall Street’s estimates.

The news comes as Pfizer and other drugmakers face pressure from President Donald Trump’s calls to slash U.S. drug prices and prepare for his planned tariffs on pharmaceuticals. Shares of Pfizer rose more than 2% in premarket trading last week.

Pfizer now expects full-year adjusted profit to be between $2.90 and $3.10 per share, up from its previous guidance of $2.80 to $3.00. The company maintained its 2025 revenue forecast of $61 billion to $64 billion.

“We raised our full-year 2025 adjusted diluted EPS guidance, demonstrating confidence in our ability to execute against our strategic priorities and deliver strong results for shareholders,” Pfizer CFO David Denton said in a release.